Iterum TherapeuticsITRMF
13F holders, Q2 2026 (June 30)2holders −16
1new positions
17sold out
$0.05avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding Iterum Therapeutics PLC (ITRMF) in their 13F filings, down 16 from Q1 2026. 1 opened new positions and 17 sold out. The largest holders were Barclays PLC ($539) and Cypress Capital Management LLC (WY) ($3).
- Company
- Iterum Therapeutics PLC
- CUSIP
- G6333L200
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $539 |
| Exits | 17 | $41K |
All 13F filers, Q1 2026 → Q2 2026: 10,795 shares bought and 1,412,998 shares sold, net −1,402,203 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Barclays PLC | 0.00% | New | 10,795 | $539 |
| Cypress Capital Management LLC (WY) | 0.00% | No change | 66 | $3 |
"% of holder's portfolio" is ITRMF's weight in each manager's 13F, not the share of Iterum Therapeutics PLC the manager owns.